Table 2.
Candidate biomarker levels among study participants by severity of CC
| Biomarker | Median (interquartile range) | |||||||
|---|---|---|---|---|---|---|---|---|
| Uninfected controls (n = 17) | T. cruzi-infected participants | P value* | ||||||
| Stage A (n = 21) | Stage B (n = 20) | Stage C (n = 27) | Control vs. A | A vs. B | B vs. C | A vs. C | ||
| QRS score | 3 (0–9) | 0 (0–3) | 6 (3–9) | 15 (9–24) | 0.099 | 0.001 | 0.003 | < 0.001 |
| BNP | 1,183 (640–1,337) | 661 (327–1,586) | 1,289 (1,074–1,903) | 2,845 (2,209–4,007) | 0.849 | 0.183 | 0.001 | < 0.001 |
| MBL | 95,461 (57,354–174,577) | 144,440 (88,698–284,726) | 184,568 (111,405–228,773) | 165,263 (95,924–285,029) | 0.271 | 0.638 | 0.561 | 0.795 |
| MMP2 | 285,349 (213,954–371,903) | 216,859 (192,329–264,988) | 277,556 (234,829–330,336) | 324,623 (296,421–666,490) | 0.020 | 0.013 | 0.089 | < 0.001 |
| MMP9 | 481,996 (332,814–749,818) | 361,305 (239,520–708,749) | 375,039 (197,756–591,389) | 238,169 (117,153–379,862) | 0.202 | 0.375 | 0.204 | 0.045 |
| TIMP1 | 185,370 (137,014–201,683) | 151,800 (131,475–181,649) | 199,684 (170,818–208,972) | 257,752 (183,586–319,857) | 0.039 | 0.003 | 0.102 | < 0.001 |
| PICP | 1,937 (1,110–2,651) | 1,644 (1,354–1,895) | 1,913 (1,591–2,183) | 1,829 (1,343–2,655) | 0.918 | 0.076 | 0.914 | 0.228 |
| PIIINP | 154 (103–333) | 241 (190–715) | 430 (188–615) | 420 (9–843) | 0.297 | 0.794 | 0.738 | 0.975 |
| TGFβ1 | 29,513 (27,935–33,227) | 28,799 (22,881–38,591) | 36,135 (32,247–40,875) | 23,479 (19,455–35,431) | 0.547 | 0.023 | 0.002 | 0.069 |
| TGFβ2 | 458 (348–689) | 687 (554–824) | 1,186 (925–1,327) | 261 (176–413) | 0.008 | < 0.001 | < 0.001 | 0.001 |
*
Wilcoxon rank sum test.
Serum biomarker concentrations are in picograms per milliliter.